Altered fecal microbiota composition in patients with major depressive disorder
The potential neuroprotective properties of GLP-1R agonists have also been demonstrated in clinical trials, with Novo Nordisk currently running a phase III clinical trial of oral semaglutide as a potential treatment option for Alzheimers disease in the announced EVOKE trial program (NCT04777409, NCT04777396)
Additionally, the psychological burden of managing a chronic condition like diabetes, combined with lifestyle changes and medication adjustments, can contribute to subjective cognitive complaints
The lawsuits name pharmaceutical companies responsible for manufacturing and marketing GLP-1 medications without adequate warnings: Novo Nordisk, the maker of Ozempic (for type 2 diabetes), Wegovy (for weight loss), and Rybelsus (oral semaglutide for diabetes) Eli Lilly, the maker of Trulicity (dulaglutide) and Mounjaro (tirzepatide), which are also GLP-1 receptor agonists associated with similar gastrointestinal risks These companies marketed their products heavily, particularly for weight loss, without fully disclosing the potential for severe and potentially permanent digestive complications